Alexion (ALXN) voluntarily recalls some vials of Soliris due to the presence of "visible particles."
According to company estimates, the recall and subsequent replacement of the vials affects ~1-2% of monthly vial consumption.
The supply of Soliris to patients won't be interrupted based on currently available information and ALXN says there have been "no identifiable safety concerns" attributed to the affected single lot. (8-K)
BofA has apparently spoken with management: The EMA agrees with the company's decision to recall the affected vials.
ALXN -1.3% premarket.